38, cours Clémenceau
About LNC TherapeuticsLNC Therapeutics is a microbiota-centric R&D company in the field of obesity and its associated cardiometabolic diseases
CEO: Jean-Luc Treillou
CFO: Fabrice Guez
FOLLOW LNC THERAPEUTCS:
Tweets by LNC Therapeutics
5 articles with LNC Therapeutics
LNC Therapeutics, a French biotech company specializing in gut microbiome-based drug research and discovery, announced formation of its Scientific Advisory Board, composed of preeminent experts in the gut microbiome and related therapeutic applications.
LNC Therapeutics raises €6.2 million for the clinical development of new generation gut microbiome based drugs
Bordeaux, France, September 05th 2019 – LNC Therapeutics, a French biotech company specializing in gut microbiome-based drug discovery, announced that it has raised €6.2 million via a capital increase and non-dilutive funding.
LNC Therapeutics announces the deployment of a research platform focused exclusively on its gut microbiome activities
LNC Therapeutics, a French biotech company specializing in gut microbiome-based drug research and development, announced the deployment of a research platform focused exclusively on its gut microbiome activities and more precisely on analysis of the therapeutic properties of christensenella.
LNC Therapeutics announces the grant of the first worldwide patent relating to the therapeutic applications of christensenella bacteria
LNC Therapeutics intends to develop a new class of drugs based on christensenella for the treatment of obesity, metabolic diseases, and other serious indications with significant unmet medical needs